Evidence map›Paper›PMID 41890300›Full record

Trial reportFrontiers in pediatrics2026

Safety and efficacy of a novel fecal microbiota transplantation method using hydrogen nanobubble water without antibiotics or bowel cleansing in children with autism spectrum disorder: an open-label, single-arm study demonstrating improvements in core and comorbidity symptoms.

Masahiko Shirotani, Shin Shimizu, Kunihiro Kitamura, Yasuhito Mikawa, Reiko Haruna, Yuichi Kawai, Seiji Koide, Ikuko Mohri, Hideo Matsuzaki, Kenji J Tsuchiya and 2 more

Abstract readClinical Trial
In one paragraph

Trial report in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Masahiko Shirotani *The Association for Clinical Research of Fecal Microbiota Transplantation Japan, Osaka, Japan.
Shin Shimizu *The Association for Clinical Research of Fecal Microbiota Transplantation Japan, Osaka, Japan.
Kunihiro KitamuraThe Association for Clinical Research of Fecal Microbiota Transplantation Japan, Osaka, Japan.
Yasuhito MikawaThe Association for Clinical Research of Fecal Microbiota Transplantation Japan, Osaka, Japan.
Reiko HarunaThe Association for Clinical Research of Fecal Microbiota Transplantation Japan, Osaka, Japan.
Yuichi KawaiThe Association for Clinical Research of Fecal Microbiota Transplantation Japan, Osaka, Japan.
Seiji KoideThe Association for Clinical Research of Fecal Microbiota Transplantation Japan, Osaka, Japan.
Ikuko MohriDepartment of Child Development, Course of Developmental Neuroscience, United Graduate School of Child Development, The University of Osaka, Suita, Osaka, Japan.
Hideo MatsuzakiResearch Center for Child Mental Development, University of Fukui, Fukui, Japan.
Kenji J TsuchiyaDepartment of Child Development, Course of Developmental Neuroscience, United Graduate School of Child Development, The University of Osaka, Suita, Osaka, Japan.
Yoshimu TanakaThe Association for Clinical Research of Fecal Microbiota Transplantation Japan, Osaka, Japan.
Taiichi KatayamaDepartment of Child Development, Course of Developmental Neuroscience, United Graduate School of Child Development, The University of Osaka, Suita, Osaka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Autism spectrum disorder (ASD) is rising in prevalence, but effective treatments for its core symptoms remain limited. Fecal microbiota transplantation (FMT) has shown promise; however, conventional methods often require antibiotics and bowel cleansing, raising concerns regarding safety and sustainability. We developed a novel FMT method using hydrogen nanobubble water and investigated its efficacy and safety. Methods: This prospective, single-arm, before-and-after comparative study enrolled 30 children aged 5-12 years with ASD, selected according to inclusion and exclusion criteria. SHIN-1, a Good Manufacturing Practice (GMP)-grade prepared fecal microbial solution from a healthy screened donor, was suspended in hydrogen nanobubble water and administered via enema. Primary outcome was the Social Responsiveness Scale-2 (SRS-2), with objectivity confirmed using Gazefinder as an eye-tracking system. Secondary outcomes included sensory profile [Short Sensory Profile (SSP)], gastrointestinal symptoms [Gastrointestinal Symptom Rating Scale [GSRS], Bristol Stool Form Scale [BSFS]] and Patient Health Questionnaire-4 items (PHQ-4). Statistical analyses employed paired t-tests or Wilcoxon signed-rank tests ( Results: At 30 weeks, fecal microbiota reconstitution was observed, with increases in short-chain fatty acid-producing and typically taxa abundant in developing children. SRS-2 scores decreased 29% ( Conclusion: This novel hydrogen nanobubble water-based FMT method was safe and effective, reducing both core and peripheral symptoms of ASD and suggesting broad benefits via the gut microbiota-brain axis.

Indexed as

anxietyautism spectrum disorderdepressionfecal microbiota transplantationgastrointestinal symptomsgut-brain axishydrogen nanobubblesafety

Identifiers

PMID41890300
PMCPMC13013415

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.